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Severe community acquired
pneumoniaAbstract Background: Severe community-acquired pneumonia (SCAP) represents a frequent and
potentially life-threatening condition. About 10% of all hospitalized patients with CAP require
admission to the intensive care unit (ICU), and the mortality of these patients reaches 20–50%.
Objective: To evaluate the clinical presentation, bacteriological proﬁle and outcome of severe
community-acquired pneumonia (SCAP).
Patients and methods: 54 patients presented by symptoms and sign of severe community
acquired pneumonia who were admitted to respiratory care unit of Alhussein, Al-Azhar University
Hospital from August 2015 to March 2016 were subjected to full clinical examination, chest X ray,
complete blood picture, sputum and blood culture, PCR for suspected cases of Inﬂuenza H1N1 and
MERS-COV, treatment, follow up, data collections and statistical analysis.
Results: The present study included 54 patients 26 males and 28 females with SCAP who were
admitted to respiratory care unit of Alhussein, Al-Azhar University Hospital. The most common
comorbidities were diabetes mellitus and hypertension. The most common presentations were fever,
cough, dyspnea and hypoxemia. Two patients developed renal failure and 4 patients developed
septic shock. The most common isolated organism was Streptococcus pneumoniae, Inﬂuenza
H1N1, and Staphylococcus aureus. Mortality was 24% and it was common in patients with
comorbidity than in patients without comorbidities.
Conclusion: SCAP occurs more frequently in those with comorbidities. Themost frequent isolated
causative organism of SCAP isS. pneumoniae, InﬂuenzaH1N1 andS. aureus. SCAP is associatedwith
signiﬁcant mortality, early recognition and prompt treatment may improve outcome.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).oo.com
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Community-acquired pneumonia (CAP) is deﬁned as an
infection of the lung parenchyma that is not acquired in a
hospital, long-term care facility, or other contact with the
health care system [1]. CAP continues to be a major cause of
morbidity and mortality. Despite the availability of adequate
anti biological agents to treat this illness, it has remained the
fourth most common cause of death in Japan since 1975 [2].
Common causative agents of pneumonia in ambulatory
patients are Streptococcus pneumoniae, Mycoplasma
pneumoniae, Haemophilus influenzae, Chlamydia pneumoniae
and respiratory viruses (inﬂuenza A and B, adenovirus, respi-
ratory syncytial virus and parainﬂuenza) [3,4]. Mortality was
the highest for Staphylococcus aureus (50%), and the lowest
for Chlamydia pneumoniae (4.5%). Mortality was not seen with
M. pneumoniae. Pneumonia due to aerobic Gram negative
organisms was uncommon, even though empirical therapy
with a combination of broad-spectrum antibiotics was often
used in this subgroup [5]. Severe community-acquired pneu-
monia (SCAP) represents a frequent and potentially life-
threatening condition. About 10% of all hospitalized patients
with CAP require admission to the intensive care unit (ICU),
and the mortality of these patients reaches 20–50% [6]. Severe
CAP has been deﬁned as those cases that require admission to
the ICU. Direct admission to an ICU is required for patients
with septic shock or acute respiratory failure requiring invasive
mechanical ventilation, which are deﬁned as major severity
criteria in the modiﬁed score of the American Thoracic Society
(ATS) guidelines that are used to deﬁne severe CAP [7].
Aim of the work
To evaluate the clinical presentation, bacteriological proﬁle
and outcome of severe community acquired pneumonia.
Study design
Prospective study.
Patients and methods
After the approval of local ethics committee 54 patients (26
males and 28 females) presented by symptoms and sign of
severe community acquired pneumonia who were admitted
to respiratory care unit of Alhussein, Al-Azhar University
Hospital from August 2015 to March 2016 were subjected to
the following:
(1) History taking: Fever, cough, pleuritic chest pain,
dyspnea, mental confusion and comorbidities.
(2) Clinical examination: Both general and local
examination of the chest.
(3) Plain chest X-ray (CXR): A chest radiograph was done
for all patients who were likely to have pneumonia to
establish the diagnosis, and follow up when needed.
(4) Chest computed tomography (CT) was done when
indicated.
(5) Laboratory Investigations: It was done in clinical pathol-
ogy department of Alhussien University Hospital, Central
laboratories of ministry of health and private laboratories.– Complete blood picture: Total leukocyte count, (TLC),
hemoglobin concentration. Blood ﬁlm to demonstrate
differential white blood cell count (WBCs) and
morphology of red blood cells (RBCs), erythrocyte
sedimentation rate (ESR) using Western Green
method. Liver function test (alanine transaminase
(ALT), aspartate transaminase (AST), alkaline
phosphatase (ALP)-total and direct bilirubin-total
proteins, and albumin. Kidney function test
(creatinine and urea) Fasting blood sugar, and Post
prandial (2 h) blood sugar.The diagnosis of severe
community acquired pneumonia (SCAP) was done
according to the Infectious Diseases Society of
America/American Thoracic Society.(6) Microbiological evaluation: Sputum, blood culture (2
samples from 2 different sites after complete aseptic con-
dition to avoid contamination), pleural ﬂuid, transtho-
racic needle aspiration, tracheobronchial aspirate, and
bronchoalveolar lavage (BAL) ﬂuid in selected cases
(BALF). Samples were plated on the following media:
blood agar, MacConkey agar, chocolate agar and
Sabouraud agar. Staining of selected samples was done
by gram stain. Urine was tested for the presence of S.
pneumoniae and Legionella antigen. Identiﬁcation of
microorganisms and susceptibility testing was
performed according to standard methods [8].
Quantitative sputum culture (QSC)
Sputum obtained from adults having clinically and/or radio-
logically diagnosed CAP. All of the samples contained
>=25 polymorphonuclear leukocytes (PNL), and <10
epithelial cells per low-power ﬁeld (LPF) under light
microscopy. Quantitative cultures were performed. Blood
and chocolate and MacConkey agar plates were used for
culture and standard microbiological methods were used
for bacterial identiﬁcation. 24 and 48 h later both direct
plates and quantitative cultures were observed. Cut off point
>=105 CFU/ml was determined to be positive for the QSC
[9].
Quantitative cultures of bronchoalveolar lavage (BAL)
ﬂuid, a colony count of P104 CFU/ml represents a bacterial
load which is indicative of bacterial pneumonia. A BAL ﬂuid
colony count below the 104 CFU/ml threshold points to
oropharyngeal contamination. Quantitative cultures of
transthoracic needle aspiration, tracheobronchial aspirate, a
colony count of P103 CFU/ml represents a bacterial load
which is indicative of bacterial pneumonia. A BAL ﬂuid
colony count below the 103 CFU/ml threshold points to
contamination [10].
Quantitative culture of the blood
A single bacterial count >100 CFU/ml in the quantitative
culture of the blood specimen in the presence of a positive
qualitative peripheral blood culture of the same organism is
an indication of sepsis [11].
Ziehl Neelsen stain: Direct smear stained with Gram stain
and Ziehl Neelsen stain (to detect acid fast bacilli).
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Inﬂuenza H1N1 and Corona virus.
Table [A]: Deﬁnition of severe community-acquired pneumonia
according to the 2007 Infectious Disease Society of America/
American Thoracic Society community-acquired pneumonia
guidelines [8].
Minor criteria: three or more of
Respiratory rate >30 breaths/min.
PaO2/FiO2 ratio <250.
Multilobar inﬁltrates.
Confusion/disorientation.
Uremia (BUN level >20 mg/dL).
Leukopenia (WBC count <4000 cells/mm3).
Thrombocytopenia (platelet count <100,000 cells/mm3).
Hypothermia (core temperature <36 C).
Hypotension requiring aggressive ﬂuid resuscitation.
Major criteria: one or more of
Invasive mechanical ventilation.
Septic shock with the need for vasopressors
Abbreviations: PaO2 = arterial oxygen tension;
FiO2 = inspiratory oxygen fraction; BUN= blood urea
nitrogen; WBC= white blood cell.Table 1 Demographic data & distribution of comorbidity
among the studied sample.
Characteristics No (%) (total no = 54)
Age in years (Mean ± SD) 44.4 ± 5.8
Gender
Male 26 (48.1%)
Female 28 (51.9%)
Comorbidities 28 (51.9%)
Male 15 (27.8%)
Female 13 (24.1%)
No comorbidities 26 (48.1%)
Males 11 (20.3%)
Females 15 (27.8%)
Comorbidities
1-Bronchial asthma 4 (7.4%)
2-Chronic bronchitis 6 (11.1%)
3-Hypertension + DM 7 (13.0%)
4-Cardiomyopathy 1 (1.9%)
5-Mitral stenosis 2 (3.7%)
6-Systemic lupus erythematosus 2 (3.7%)
7-Liver cirrhosis 1 (1.9%)
8-Pulmonary ﬁbrosis 1 (1.9%)
9-Hypogammaglobulinemia 1 (1.9%)
10-Wagner,s granulomatosis 1 (1.9%)
11-Septic emboli 1 (1.9%)
12-Hodgkin’s lymphoma 1 (1.9%)Inpatient, ICU treatment [8]
(1) A beta-lactam (cefotaxime, ceftriaxone, or ampicillin–
sulbactam) plus either azithromycin (level II evidence)
or a ﬂuoroquinolone (level I evidence) (strong recom-
mendation) (For penicillin-allergic patients, respiratory
ﬂuoroquinolone and aztreonam are recommended.)
(2) For Pseudomonas infection, use an antipneumococcal,
antipseudomonal beta-lactam (piperacillin–tazobactam,
cefepime, imipenem, or meropenem) plus either cipro-
ﬂoxacin or levoﬂoxacin (750-mg dose) or the above
beta-lactam plus an aminoglycoside and azithromycin
or the above beta-lactam plus an aminoglycoside and
an antipneumococcal ﬂuoroquinolone (for penicillin-
allergic patients, substitute aztreonam for the above
beta-lactam). (Moderate recommendation; level III
evidence.)
(3) For community-acquired methicillin-resistant S. aureus
infection, add vancomycin or linezolid. (Moderate
recommendation; level III evidence).
Statistical analysis of data
Statistical analysis was carried out using the SPSS computer
package version 17.0 (SPSS Inc., Chicago, IL, USA). The
collected data were statistically managed as follows:
– For descriptive statistics: mean ± SD were used for
quantitative variables while the number and percentage
were used for qualitative variables.
– For analytic statistics: chi-square test was used to assess the
differences in frequency of qualitative variables, while
Fischer’s exact test (FET) was applied if any expected cell
values in a 2´2 table was <5.– In order to assess the differences in means of quantitative
variables between both groups, independent sample t-test
was applied.
– The statistical methods were veriﬁed, assuming a signiﬁcant
level of P< 0.05 and a highly signiﬁcant level of
P< 0.001.
Results
The present study included 54 patients 26 males and 28 females
with SCAP. From 54 there were 28 patients 15 males and 13
females with comorbidities and 26 patients 11 males and 15
females without comorbidities. The most common comorbidi-
ties was diabetes mellitus and hypertension (13%), chronic
bronchitis (11.1%) and bronchial asthma (7.4%) (Table 1).
As regards clinical presentation, fever was present in 85.7%
of patients with comorbidities compared to 100% in patients
without comorbidities, cough 100%, shortness of breath
92.5%, hypoxemia was 82.1% in patients with comorbidities
compared to 76.9% in patients without comorbidities, expec-
toration was 78.6% in patients with comorbidities compared
to 73.1% in patient without comorbidities, confusion was
25% in patients with comorbidities compared to 7.7% in
patients without comorbidities. Low systolic blood pressure
(BP) was 39.3% in patients with comorbidities compared to
11.5% in patients without comorbidities, low diastolic BP
was 35.7% in patients with comorbidities compared to 7.7%
in patients without comorbidities, differences were statistically
signiﬁcant. Complication in form of renal failure occurred in
7.1% and septic shock in 14.3% in patients with comorbidities
Table 2 Comparison between patients with and without comorbidities regarding clinical presentation.
Clinical presentation Patients with comorbidities no = 28 (%) Patients without comorbidities no = 26 (%) P-value
Fever > 38.5 24 (85.7) 26 (100.0) 0.112
Cough 28 (100.0) 26 (100.0) –
Shortness of breath 26 (92.9) 24 (92.3) 1.000
Expectoration 22 (78.6) 19 (73.1) 0.754
Confusion 7 (25.0) 2 (7.7) 0.144
PaO2/FiO2 <250 23 (82.1) 20 (76.9) 0.741
Systolic blood pressure <90 mmHg 11 (39.3) 3 (11.5) 0.030*
Diastolic blood pressure <60 mmHg 10 (35.7) 2 (7.7) 0.021*
Complications
Renal failure 2 (7.1) 0 (0.0) 0.2611
Septic shock 4 (14.3) 2 (7.7)
No complications 22 (78.6) 24 (92.3)
Values analyzed by Fisher’s exact test.
1 Values analyzed by Chi-square test.
* Signiﬁcant.
Table 3 Comparison between patients with and without comorbidities regarding initial laboratory investigations.
Laboratory investigations Patients with comorbidity no = 28 Patients without comorbidity no = 26 P-value
Hemoglobin (g/dL) 10.5 ± 2.3 14.8 ± 2.1 <0.001*
Total leukocyte count (109/L) 16.3 ± 5.1 15.4 ± 5.0 0.529
Neutrophils (%) 84.4 ± 8.3 78.3 ± 7.9 0.007*
Lymphocytes (%) 28.2 ± 7.6 31.1 ± 6.2 0.142
Platelets (109/L) 223.0 ± 55.0 243.0 ± 68.4 0.242
Serum BUN (mg/dL) 45.6 ± 6.1 35.6 ± 4.8 <0.001*
Serum creatinine (mg/dL) 2.2 ± 0.8 1.1 ± 0.6 <0.001*
Serum sodium (mmol/L) 139.1 ± 5.0 135.0 ± 3.4 0.001*
Serum potassium (mmol/L) 3.6 ± 1.4 4.2 ± 0.7 0.056
ABG
PH 7.26 ± 0.09 7.36 ± 0.08 <0.001*
PaCo2 (mmHg) 48.1 ± 8.7 33.0 ± 4.6 <0.001
*
PaO2 (mmHg) 41.1 ± 7.5 49.1 ± 7.9 <0.001
*
Values present as mean ± SD and analyzed by independent samples t-test.
* Signiﬁcant.
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comorbidities, the difference was statistically non signiﬁcant
(see Table 2).
Table 3 showed initial laboratory investigation, complete
blood picture, blood urea nitrogen, serum creatinine, serum
sodium, serum potassium and blood gas analyses. The differ-
ence between both groups was statistically signiﬁcant as
regards hemoglobin which was low in patients with comorbidi-
ties, high neutrophils count, high blood urea and serum
creatinine in patients with comorbidities, compared to patients
without comorbidities. Low PH and PaO2 with high PaCo2 in
patients with comorbidities compared to patients without
comorbidities the differences was statistically signiﬁcant.
Table 4 showed chest X-ray ﬁnding. Bilateral patchy inﬁl-
trate in 35.1%, bilateral patchy inﬁltrate with cavitations in
3.7%, bilateral lower lobes inﬁltrate in 16.6%, bilateral lower
lobes consolidation with pleural effusion in 3.7%, right lower
lobe consolidation in 14.8%, left lower lobe consolidation in
11.1%, right upper lobe consolidation with cavitations
in 3.7% and right lower lobe consolidation with cavitations
in 3.7% and right lower lobe consolidation and pleural
effusion in 7.4%.Table 5 showed sputum culture results, S. pneumoniae was
the most common organism, it occurred in 18.5%, S. aureus in
11.1%, Inﬂuenza H1N1 in 12.9%, Klebsiella pneumonia in
7.4%, H. influenzae in 9.2%, Moraxella catarrhalis in 3.7%,
Legionella species in 1.8%, Pseudomonas aeruginosa in 5.5%,
Acinetobacter baumannii in 3.7%, and Mycobacterial
tuberculosis in 1.8%. No bacterial growth occurred in 24%.
Table 6 showed blood culture result of both groups,
organism isolated only in (31.5%), the organisms isolated were
Escherichia coli in 7.4%, S. pneumoniae in 5.5%, S. aureus in
5.5%, K. pneumonia in 5.5%, P. aeruginosa in 1.8%, and A.
baumannii in 3.7%.
Table 7 showed that 42.9% from patients with comorbidities
needed invasive mechanical ventilation compared to 23.1% for
patient without comorbidities, and 21.4% from patients with
comorbidities needed non invasive mechanical ventilation com-
pared to 19.2% for patients without comorbidity. Inotropic
support needed in 21.4% of patients with comorbidities com-
pared to 7.7% in patients without comorbidities. ICU stay
was 7 ± 1.2 days for patients with comorbidities compared to
4 ± 0.9 days for patients without comorbidities. Hospital stay
was 13 ± 1.5 days for patients with comorbidities compared
Table 4 Chest X-ray ﬁnding.
Chest X-ray ﬁnding Causative organism No No= 54 (%)
1-Bilateral patchy inﬁltrate – Inﬂuenza H1N1 7 19 (35.1%)
– Staphylococcus aureus 5
– Hemophilus influenza 4
– Streptococcus pneumonia 3
2-Bilateral patchy inﬁltrate with cavitations – Pseudomonas aeruginosa 1 2 (3.7%)
– Staphylococcus aureus 1
3-Bilateral lower lobes inﬁltrates – Streptococcus pneumonia 5 9 (16.6%)
– Moraxella catarrhalis 3
– Klebsiella pneumonia 1
4-Bilateral lower lobes consolidation with pleural eﬀusion – Acinetobacter baumannii 1 2 (3.7%)
– Streptococcus pneumonia 1
5-Right lower lobe consolidation – E. coli 4 8 (14.8%)
– Pseudomonas aeruginosa 3
– Streptococcus pneumonia 1
6-Left lower lobe consolidation – Streptococcus pneumonia 2 6 (11.1%)
– Klebsiella pneumonia 2
– Hemophilus influenza 1
– Acinetobacter baumannii 1
7-Right upper lobe consolidation and cavitations – Mycobacterium tuberculosis 1 2 (3.7%)
– Klebsiella pneumonia 1
8-Right lower lobe consolidation and cavitations – Acinetobacter baumannii 1 2 (3.7%)
– Klebsiella pneumonia 1
9-Right lower lobe consolidation and pleural eﬀusion – Acinetobacter baumannii 1 4 (7.4%)
– Klebsiella pneumonia 1
– Legionella species 1
– Hemophilus influenza 1
Table 5 Comparison between patients with and without comorbidities regarding sputum culture.
Sputum culture Patients with comorbidities
no = 28 (%)
Patients without comorbidities
no = 26 (%)
Total P-value
1-Streptococcus pneumonia 5 (17.9) 5 (19.2) 10 (18.5%) 1.000
2-Hemophilus inﬂuenza 3 (10.7) 2 (7.7) 5 (9.2%) 1.000
3-Moraxella catarrhalis 1 (3.6) 1 (3.8) 2 (3.7%) 1.000
4-Staphylococcus aureus 3 (10.7) 3 (11.5) 6 (11.1%) 1.000
5-Legionella species 1 (3.6) 0 (0.0) 1 (1.8%) 1.000
6-Klebsiella pneumonia 4 (14.3) 0 (0.0) 4 (7.4%) 0.112
7-Pseudomonas aeruginosa 3 (10.7) 0 (0.0) 3 (5.5%) 0.237
8-Acinetobacter baumannii 2 (7.1) 0 (0.0) 2 (3.7%) 0.491
9-Inﬂuenza H1N1 4 (14.3) 3 (11.5) 7 (12.9%) 1.000
10-Mycobacterium tuberculosis 1 (3.6) 0 (0.0) 1 (1.8%) 1.000
11-Negative 0 (0.0) 13 (50.0) 13 (24%) <0.001*
Values analyzed by Fisher’s exact test.
* Signiﬁcant.
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was 32.1% for patients with comorbidities compared to
15.3% for patients without comorbidities, the total mortality
was 24%.
Mortality was 100% in patients with A. baumannii mul-
tidrug resistant (MDR) pneumonia, (66.6%) in patients with
P. aeruginosa pneumonia, 50% in patients with K. pneumonia,
33.3% in patients with S. aureus pneumonia, 28.5% in patients
with Inﬂuenza H1N1 pneumonia, and 33% in patients with S.
pneumoniae (see Table 8, Figs. 1–4).Discussion
Severe community acquired pneumonia (SCAP) occurs in
approximately 18–36% [12] of all CAP. The mortality rate
for CAP is <5% for outpatient cases, it rises to 10% in admit-
ted ward patients and can exceed 30% in patients admitted to
intensive care unit (ICU) [13]. In our study 28 out of 54
patients (51.85%) admitted with SCAP had comorbidities.
The most common comorbidities were diabetes mellitus and
hypertension (13%), chronic bronchitis (11.1%) and bronchial
Table 6 Comparison between patients with and without comorbidity regarding blood culture.
Blood culture Patients with comorbidity
no = 28 (%)
Patients without comorbidity
no = 26 (%)
Total no = 54(%) P-value
1-Streptococcus pneumonia 2 (7.1) 1 (3.8) 3 (5.5) 1.000
2-Hemophilus influenza 1 (3.6) 0 (0.0) 1 (1.8) 1.000
3-Staphylococcus aureus 2 (7.1) 1 (3.8) 3 (5.5) 1.000
6-Klebsiella pneumoniae 3 (10.7) 0 (0.0) 3 (5.5) 0.237
7-Pseudomonas aeruginosa 1 (3.6) 0 (0.0) 1 (1.8) 1.000
8-Acinetobacter baumannii 2 (7.1) 0 (0.0) 2 (3.7) 0.491
7-E. coli 3 (10.7) 1 (3.8) 4 (7.4) 0.612
8-No growth 14 (50.0) 23 (88.5) 37 (68.5) 0.003*
Values analyzed by Fisher’s exact test.
* Signiﬁcant.
Table 7 Comparison between patients with and without comorbidities regarding the need for mechanical ventilation (MV), hospital
stay & mortality.
Patients with comorbidities
no = 28 (%)
Patients without comorbidities
no = 26 (%)
Total no = 54 (%) P-value
Needed invasive MV 12 (42.9) 6 (23.1) 18 (33.3) 0.155
Needed non invasive MV 6 (21.4) 5 (19.2) 11 (20.4) 1.000
Inotropic support 6 (21.4) 2 (7.7) 8 (14.8) 0.253
ICU stay in days1 7.0 ± 1.2 4.1 ± 0.9 5.6 ± 1.8 <0.001*
Hospital stay in days1 13.0 ± 1.5 8.0 ± 1.6 10.6 ± 2.9 <0.001*
Mortality 9 (32.1) 4 (15.3) 13 (24) 0.207
Values analyzed by Fisher’s exact test.
1 Values present as mean ± SD & analyzed by independent samples t-test.
* Signiﬁcant.
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lupus erythematosus, 1 patient diagnosed as Hodgkin’s lym-
phoma, 2 patients diagnosed as severe mitral stenosis, 1 patient
diagnosed as Wagner’s granulomatosis, 1 patient diagnosed as
Hypogammaglobulinemia and 1 patient diagnosed as Septic
pulmonary emboli, and all these 8 patients were diagnosed
for the ﬁrst time.
In this study the most common clinical presentations were
fever, cough, dyspnea and hypoxemia. 2 patients developed
acute renal failure and 6 patients developed septic shock. In
study done by Aya et al. [14], they found that (72.2%) was
complaining of fever, (89.9%) was complaining of cough,
sputum production was present in (66.66%), dyspnea was pre-
sent in (66.6%), pleuritic chest pain was present in (35.11%),
and non respiratory complaints in the form of nausea,
vomiting, myalgia and headache were found in (38.69%).
In our study there was a low hemoglobin level, high
neutrophil count, elevated blood urea and serum creatinine
with low PH, high PaCo2 and low PaO2 in patients with
comorbidities compared to patients without comorbidities,
the differences were statistically signiﬁcant. This indicates
more severe diseases and multiple organ dysfunction in
patients with comorbidities.
In this study chest X-ray showed Bilateral patchy inﬁltrate
in 35.1% which is common with Inﬂuenza A H1N1, S. aureus,Haemophilus influenza, and S. pneumoniae; bilateral patchy
inﬁltrate with cavitations in 3.7%, and it was common with
S. aureus, and P. aeruginosa; bilateral lower lobes inﬁltrate
in 16.6% which occurred with S. pneumoniae, M. catarrhalis,
and Klebsiella pneumonia; bilateral lower lobe consolidation
with pleural effusion in 3.7%; right lower lobe consolidation
in 14.8%; left lower lobe consolidation in 11.1%; right upper
lobe consolidation in 3.7% and right lower lobe consolidation
with cavitations in 3.7% and right lower lobe consolidation
and pleural effusion in 7.4%. In the study done by Kantor
[15] he found the patterns of lobar pneumonia and bronchop-
neumonia were equally frequent in pneumococcal pneumonia.
The radiographic ﬁndings of Legionella consist of segmental
peripheral consolidations, there may also be lobar involve-
ment, and bilateral disease is seen in more than half of the
patients [16]. Viral pneumonia has a radiologic pattern consist-
ing of poorly deﬁned air-space nodules of 4–10 mm, patchy
areas of peribronchial ground glass opacity, and air-space con-
solidation. Hyperinﬂation is also commonly present because of
the associated bronchiolitis. Pneumonia could progress as seen
by the rapid conﬂuence of consolidation leading to diffuse
alveolar damage, which consists of homogenous or patchy
unilateral or bilateral air-space consolidation and ground-
glass opacity or poorly deﬁned centrilobular nodules [17].
The predominant radiographic patterns in H1N1 pneumonia
Table 8 Percentage of mortality according to causative
organism.
Causative organism Percentage of mortality
no = percentage (%)
Inﬂuenza H1N1 2/7 (28.57%)
Staphylococcus aureus 2/6 (33.3%)
Acinetobacter baumannii MDR 2/2 (100%)
Klebsiella pneumoniae 2/4 (50%)
Pseudomonas aeruginosa 2/3 (66.6%)
Streptococcus pneumonia 3/10 (33%)
Figure 1 Chest X ray of 40 year old female with severe CAP.
Figure 2 Chest X ray of 35 year old male with severe CAP.
Figure 3 Chest X ray of 38 year female with severe CAP.
Figure 4 CT chest of 53 year male patient with severe CAP.
Clinical presentations and outcome of SCAP 837are bilateral ground glass opacity and alveolar consolidation
[18]. Striking characteristic of S. pneumonia is its tendency to
involve the pleura, parapneumonic effusions are common in
Pneumococcal pneumonia [19]. In the study conducted by Ali
Khawaja et al. [20] they found that the most common chest
X ray ﬁnding in patient with CAP was lobar consolidation
in (63%) followed by pleural effusion in (37%) and interstitial
inﬁltrates in (28%). In another study by Seksan et al. [21] they
found that the most common pulmonary inﬁltration pattern of
X-ray in patients with CAP was patchy inﬁltrates in (69.3%),
followed by interstitial inﬁltrations in (22.2%), diffuse alveolar
inﬁltrations in (5.0%) and multilobar inﬁltrations in (3.5%).In this study, sputum culture showed that S. pneumoniae
was the most common isolated organism, it occurred in
18.5%, S. aureus in 11.1%, Inﬂuenza H1N1 in 12.9%, K. pneu-
monia in 7.4%, H. influenzae in 9.2%, M. catarrhalis in 3.7%,
Legionella species in 1.8%, P. aeruginosa in 5.5%, A. bauman-
nii multidrug resistant (MDR) in 3.7%, and M. tuberculosis in
1.8%. No bacterial growth occurred in 24%. P. aeruginosa, K.
pneumonia, E. coli and A. baumannii were predominantly pre-
sent in patients with comorbidities, which can be explained by
airway colonization by these organisms, also Inﬂuenza H1N1
is considered high because our study was done mainly during
winter season. In the study done by Boixeda et al. [22], they
found that the most frequently isolated microorganism in
patients with comorbidities and COPD was P. aeruginosa in
27 (30.7%), followed by S. pneumoniae in 23 (26.1%), Enter-
obacteriaceae in 18 (20.4%), H. influenza in 14 cases
(15.9%), and ﬁnally M. catarrhalis in 6 (6.8%). In another
study done File [4] he found that the most common causes
of severe pneumonia are S. pneumoniae, S. aureus, Legionella
spp. Gram-negative bacilli and H. influenza.
In our study blood culture showed that organism isolated
only in 50 % of patients with comorbidities compared to
838 M. Elshamly et al.11.5% in patients without comorbidities, the difference was
statistically signiﬁcant, the organisms isolated were E. coli in
7.4%, S. pneumoniae in 5.5%, S. aureus in 5.5%, K. pneumonia
in 5.5%, P. aeruginosa in 1.8%, A. baumannii in 3.7%.
Khawaja et al. [20] found that blood cultures were positive
in 15 patients (13.3%) with severe CAP and in 9 patients
(6.1%) with non-severe CAP, there were signiﬁcantly more
patients with positive blood cultures among those with severe
CAP than non severe CAP.
In our study 42.9% from patients with comorbidities needed
invasive mechanical ventilation compared to 23.1% for patient
without comorbidities, and 21.4% from patients with
comorbidities needed non invasive mechanical ventilation com-
pared to 19.2% for patient without comorbidities. Inotropic
support was needed in 21.4% of patients with comorbidities
compared to 7.7% in patients without comorbidities, ICU stay
was 7 ± 1.2 days for patients with comorbidities compared to
4 ± 0.9 days for patients without comorbidities. Hospital stay
was 13 ± 1.5 days for patients with comorbidities compared to
8 ± 1.6 days for patients without comorbidities. Previous stud-
ies by Sreekanth A and Praveen Kumar Reddy. [23] they found
that the hospital stay was longer for patients with comorbidities
compared to patients without comorbidities, the most frequent
complication recorded was sepsis in 38 cases (31%) in patients
with comorbidity and 19% in patients without comorbidity,
and sepsis was the cause of death in 57% cases. Previous studies
by Yoshimoto et al. [24] admit that septic shock was associated
with higher mortality and is a frequent complication.
In our study mortality was 32.1% for patients with comor-
bidities compared to 15.3% for patients without comorbidities,
the total mortality was 24%. In our study the infection with P.
aeruginosa was associated with worst outcome as 3 out of 3
patients infected with this pathogens died. Internationally the
reported mortality of patients with severe CAP is between
35.8% and 39.1% at 5 years [25]. Mortality in patients infected
with P. aeruginosa was 66.6%, the lowest mortality was with
streptococcal pneumonia 22.2% [25]. In the study done by
Yoshimoto et al. [24], the mortality rate for SCAP requiring
ICU admission was 48.6%.
The major limitation of our study was the lack of availabil-
ity of serological tests for the diagnosis of viral and atypical
pathogens.
Conclusion
SCAP occurs more frequently in those with comorbidities. The
most frequent causative organism of SCAP isolated is
S. pneumoniae, Inﬂuenza H1N1and S. aureus. SCAP is
associated with signiﬁcant mortality, early recognition and
prompt treatment may improve outcome.
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